Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...
More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...
Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...
Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...
Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...
The world’s second-richest person launched the Courage and Civility Award in 2021 to support philanthropists—and Eva Longoria ...